References:

- [1] Fries JF, Spitz P, Kraines RG, Holamn HR: Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980; 23: 137–45.
- [2] Pincus T. Are Patient Questionnaire Scores as “Scientific” as Laboratory Tests for Rheumatology Clinical Care? *Bull NYU Hosp Jt Dis.* 2010;68(2):130–139.
- [3] Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. *Source Code for Biology and Medicine.* 2008;3:17. doi:10.1186/1751-0473-3-17.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5544

SAT0122 WHICH MULTIMORBID CONDITIONS ARE MORE PREVALENT AROUND THE TIME OF EARLY RA DIAGNOSIS AND HAVE THE GREATEST IMPACT ON TRAJECTORIES OF DISEASE ACTIVITY IN THE FIRST YEAR? RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT

O. Schieir¹, S.J. Bartlett^{2,3}, C. Hitchon⁴, J. Pope⁵, G. Boire⁶, B. Haraoui⁷, E. Keystone¹, D. Tin⁸, C. Thorne⁸, V.P. Bykerk^{1,9} on behalf of Canadian Early Arthritis Cohort Canada (CATCH) Investigators. ¹University of Toronto, Toronto; ²McGill University, Montreal, Canada; ³Johns Hopkins University, Baltimore, United States; ⁴University of Manitoba, Winnipeg; ⁵Western University, London; ⁶Université de Sherbrooke, Sherbrooke; ⁷Institut de Rhumatologie de Montreal, Montreal; ⁸Southlake Regional Health Center, Newmarket, Canada; ⁹Hospital for Special Surgery, New York, United States

Background: Multimorbidity (MM) is highly prevalent in early RA (ERA), and higher counts of conditions are associated with poorer disease control¹. It is important to understand the number of, and which specific conditions most affect disease presentation, early therapies and disease activity over time.

Objectives: To estimate the prevalence of MM conditions at the time of ERA diagnosis and associations with ERA clinical characteristics, early treatment, and trajectory of disease activity in the 1st year of follow up.

Methods: Data were from ERA patients (<1-year of symptoms) enrolled in CATCH (Canadian Early Arthritis Cohort) who met 1987 or 2010 RA criteria, and had at least two DAS28 measures in the first year. We examined baseline prevalence of: 1) cardiovascular disease (CVD), 2) diabetes, 3) cancer, 4) pulmonary disease, 5) bowel disease, 6) other rheumatic diseases, and 7) psoriasis, obtained from patient-reports of physician-diagnosed medical conditions, 8) obesity (BMI≥30), and 9) depressive symptoms (RAND-12 <42). We compared baseline demographic and clinical characteristics in ERA + each condition vs. ERA alone. We estimated adjusted effects of each condition on early use of RA therapies with logistic regression and adjusted effects of each condition on DAS28 trajectory over the first year of follow up with linear growth models.

Results: The sample included 1,595 patients, 1153 (72%) were female, with a mean (sd) age of 54 (15) years and 6 (3) months of symptoms. At baseline 1,434 (92%) were treated with conventional DMARDs (mostly methotrexate (76%)) and 33 (2%) with a biologic. More than 70% of ERA patients reported at least one MM, and over 30% reported 2+ MMs. Patients with MM were often older and had higher disease activity at baseline, with variations by condition. Patients with RA+CVD or depressive symptoms had a 60% and 90% higher adjusted odds of baseline steroid use, respectively (p<.001). In fully adjusted growth models, relative to patients with ERA only, patients with: a) diabetes, other rheumatic diseases or depressive symptoms had higher baseline DAS28 scores and less improvement over time, b) pulmonary disease, bowel disease, psoriasis or obesity had similar baseline DAS28 scores but less improvement over time; and c) CVD or cancer had higher baseline DAS28 scores but similar improvement over time (all p<0.05).

Conclusions: Multimorbidity is common in ERA patients seen in routine practice and associated with higher disease activity at baseline, less improvement over time, or both, and a greater likelihood of prescribing steroids for certain conditions. Integrating MM in to current RA care strategies may help achieve better patient outcomes.

References:

- [1] Hitchon CA, et al. Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. *Rheumatology.* 2016. doi: 10.1093/rheumatology/kew061.

Disclosure of Interest: O. Schieir: None declared, S. Bartlett Consultant for: UCB, Pfizer, C. Hitchon: None declared, J. Pope Grant/research support from: Amgen, BMS, Pfizer, Roche, UCB, Consultant for: AbbVie, Actelion, Amgen, Bayer, BMS, Genzyme, Hospira, Lilly, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, UCB, G. Boire: None declared, B. Haraoui Grant/research support from: AbbVie, Amgen, BMS, Janssen, Pfizer, Roche and UCB, Consultant for: AbbVie, Amgen, BMS, Celgene, Eli Lilly Janssen, Merck, Pfizer, Roche and UCB, Speakers bureau: Amgen, BMS Janssen, Pfizer and UCB, E. Keystone Grant/research support from: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, F.Hoffmann-La Roche Inc, Janssen Inc, Lilly Pharmaceuticals, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis, UCB, Consultant for: Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Crescendo Bioscience, F Hoffmann-La Roche Inc, Genentech Inc, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Speakers bureau: Abbott Laboratories, AstraZeneca LP,

Bristol-Myers Squibb Canada, F Hoffmann-La Roche Inc, Janssen Inc, Pfizer Pharmaceuticals, UCB, Amgen, D. Tin: None declared, C. Thorne: None declared, V. Bykerk: None declared

DOI: 10.1136/annrheumdis-2017-eular.6369

SAT0123 MULTIDIMENSIONAL EVALUATION OF PAIN IN RHEUMATOID ARTHRITIS

P. Vergne-Salle¹, S. Pouplin², A. Bera-Louville³, M. Soubrier⁴, C. Richez⁵, R.-M. Javier⁶, S. Perrot⁷, P. Bertin¹. ¹Rheumatology, University Hospital, Limoges; ²Rheumatology, University Hospital, Rouen; ³Rheumatology, University Hospital, Lille; ⁴Rheumatology, University Hospital, Clermont-Ferrand; ⁵Rheumatology, University Hospital, Bordeaux; ⁶Rheumatology, University Hospital, Strasbourg; ⁷Pain center, University Hospital, Paris, France

Background: Although pain in rheumatoid arthritis (RA) is frequently thought to be inflammatory in nature, some studies reported clinically significant pain despite relatively low rheumatoid arthritis (RA) disease activity. Less than 50% of patients are satisfied by the management of pain.

Objectives: to report a recent multidimensional evaluation of pain in a large RA population.

Methods: Patients with RA were enrolled in 7 French Rheumatology Centers during a visit or a hospitalization in a transversal observational study. Socio-demographic data, previous and prescribed medications, disease duration, immunologic status, DAS28 score were assessed. Patients completed the multidimensional pain questionnaire from french health authority, the health assessment questionnaire (HAQ), the Beck depression scale and the anxiety scale STAI. Joint damage was evaluated by a simple erosion narrowing score.

Results: Of the 299 screened patients, 295 were included with a mean age of 58.4±11.7 years, 80.3% of female, a mean disease duration of 13.2±9.6 years, positivity of rheumatoid factors in 76.4%, anti-citrullin antibodies in 74% of cases. Concerning medications, 42.7% were treated by corticoids (mean dose=6.4 mg/d), 66% by analgesic drugs (64.1% with acetaminophen, 45.6% weak opioids, 7.1% strong opioids) and 24.4% with NSAIDs. The RA treatments were DMARDs in 69.1% and biotherapies in 82.7% of cases. The mean DAS-28 score was 3.1±1.3 with 38.7% of patients in remission and 15.4% in low disease activity. The verbal scale for satisfaction about pain management showed that a third of patients was very satisfied, the half satisfied, 16% weakly or not satisfied. The mean pain visual analogic scale (VAS) for the last 8 days was 33.6 mm ±26.5/100. 39% of patients had a pain VAS >40 mm/100. The Beck scale showed a moderate to severe depression in 34,3% of patients. Anxiety was present in 57.5%. The impacts of pain on daily behaviors were more important on work. The pain VAS for the 8 days was correlated with the score of depression et with the DAS-28 score (p<0.0001). The population with a pain VAS >40 mm had a significant more important Beck score, anxiety score, HAQ, DAS-28 score and had more impacts of pain on daily behaviors. There was no association between pain and structural damage and disease duration. There was no difference between the populations with VAS>40 or <40 mm in terms of IL-6, IL-17 and IL-33 serum levels. The multidimensional evaluation of pain wasn't different between treatment groups (DMARDs, biotherapies) and between the different biotherapies. Multivariate analysis with principal component analysis

found statistically significant associations between pain VAS and depression score, impacts of pain on daily behaviors and between pain VAS and DAS-28.

Conclusions: Almost 40% of patients had moderate to severe pain in a population of severe RA followed in hospital centers and treated with biotherapies in more than 80% of cases. Therefore, pain is still a major outcome to consider in RA. But, the proportion of patients with moderate to severe pain is less important than that one published by Taylor et al. Pain is associated with the DAS-28 score, but also with the depression score.

References:

[1] Taylor P et al. *J Int Med Res* 2010; 38: 1213–24.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3287

SAT0124 HIGHER BMI AND SHORTER DISEASE DURATION ARE ASSOCIATED WITH "FIBROMYALGIC" RHEUMATOID ARTHRITIS – EVALUATION USING POWER DOPPLER ULTRASONOGRAPHY

P. Cheung, M. Lahiri. *Rheumatology, National University Hospital, Singapore, Singapore, Singapore*

Background: Power Doppler ultrasonography (PDUS) can differentiate RA patients who truly have active disease. Patients with persistent joint tenderness may not necessarily have true inflammation; yet composite disease activity indices remain high, leading to treatment escalation. These patients are often referred to having "fibromyalgic RA" where tender joints far exceed that of swollen joints.

Objectives: We evaluated the predictors of "fibromyalgic RA (FMRA)," defined as patient-reported tender joint count (TJC) at least 7 greater than PDUS joint count.

Methods: Consecutive RA patients were recruited in a tertiary rheumatology centre in Singapore. Patients self-assessed 28 joints for tenderness, followed by blinded PDUS assessment of the corresponding joints. Patients were grouped into either, (i) PDUS joint count > patient-reported TJC, (ii) PDUS joint count = patient-reported TJC (iii) patient-reported TJC > PDUS joint count, (difference <7) (iv) patient-reported TJC > PDUS joint count, (difference ≥7). Group (iv) is defined as FMRA. Predictors of FMRA were evaluated by multinomial logistic regression.

Results: Of the 101 patients, 81% were female, 72% Chinese, median age of 53.8 (IQR 48.1;62.4) and disease duration of 6.2 (1.9;8.8) years. Median BMI was 23.6 (20.8;27.0) and DAS28 was 3.2 (2.5;4.2). FMRA patients (15%) had a high median patient-reported TJC of 13 (10;18) but low median PDUS joint count of 1 (0;4). Compared to the other groups, they had higher median DAS28 of 4.6 (3.3;5.2), shorter mean disease duration of 2.3 (0.4;6.8) years, and higher median BMI of 26.9 (23.7;32.2). No differences in mean ESR or proportion of patients with seropositive disease were observed. Using Group (i) as the reference, patients with FMRA were more likely to have a higher BMI (adjusted OR=1.6, 95% CI 1.2; 2.1, p=0.001 for every unit increase) and shorter disease duration (adjusted OR=0.8, 95% CI 0.7;0.98, p=0.03 for every additional year). Age, gender, ethnicity, disease activity (PDUS score) and seropositivity were not significant predictors of FMRA.

Conclusions: Higher BMI and shorter disease duration were independent predictors of FMRA. Use of PDUS would be useful in this group, rather than basing treatment decisions on composite disease activity indices alone.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.1598

SAT0125 TENOSYNOVITIS IN RHEUMATOID ARTHRITIS: PREVALENCE AND DETERMINANTS OF TENOSYNOVITIS DETECTED IN THE SONAR-ULTRASOUND EXAMINATION IN THE SCQM COHORT

R. Micheroli¹, A. Scherrer², L. Brulhardt³, H. Ziswiler⁴, P. Zufferey⁵, B. Möller⁶, A. Ciurea¹, G. Tamborini⁷. ¹USZ; ²SCQM, Zurich; ³Hôpital Neuchâtelais, la Chaux-de-Fonds; ⁴OsteoRheuma, Bern; ⁵CHUV, Lausanne; ⁶Inselspital, Bern; ⁷Ultrasound Center Rheumatology, Basel, Switzerland

Background: Tenosynovitis is one of the common features of rheumatoid arthritis (RA). The diagnosis of tenosynovitis is frequently made clinically but for the detection of tenosynovitis, ultrasound (US) is more sensitive. US and MRI detected tenosynovitis is a predictor for unstable remission and erosive progression in RA.

Objectives: The aim of this study was to assess the prevalence and determinants of TS detected in the SONAR (Swiss Sonography Group in Arthritis and Rheumatism) examinations in patients with Rheumatoid Arthritis in the SCQM Cohort.

Methods: The SONAR ultrasound examination consists of a semi-quantitative score employing both multiplanar gray scale (B-mode) and Doppler-mode (PwD) and a TS composite score (grade 0–3). Pathologic TS was defined as TS grade 2–3. Characteristics of patients with and without TS are shown using standard descriptive methods. In a longitudinal sub-group the change in TS from no TS to pathologic TS or vice versa and DAS28 over time was categorized as "worse" (Δ DAS28 ≥ 2.1), "same" and "better" (Δ DAS28 ≤ -2.1) and the correlation between change DAS28 and in tenosynovitis was evaluated.

Results: 941 RA patients with TS score were available. 20% of included patients showed signs of TS. The presence of TS was associated with male gender and

higher values of disease activity and physical function disability. Furthermore, 15% of patients in DAS28 Remission had sonographic TS. TS was less frequently observed in patients on biologic therapies (Table 1). The longitudinal sub-group consisted of 348 patients. The correlation between change in DAS28 and change in TS was poor (polychoric correlation 0.28 [0.14, 0.43]).

Table 1. Patient Characteristics at first Tenosynovitis measurement

Parameter	Tenosynovitis		OR [95% CI]
	Yes (N=184)	No (N=757)	
Male gender, n (%)	59 (32)*	158 (21)*	1.8 [1.2, 2.5]*
Mean age in years	57	56	1.0 [0.99, 1.02]
Mean disease duration in years	5	3	0.98 [0.96, 1.00]
RF positive, n (%)	123 (68)	511 (70)	0.9 [0.7, 1.3]
Anti-CCP positive, n (%)	109 (65)	477 (70)	1.1 [0.6, 2.1]
DAS28 Remission, n (%)	24 (15)*	232 (38)*	0.3 [0.2, 0.5]*
Mean DAS28	3.9*	3.1*	1.6 [1.4, 1.8]*
Mean B-Mode SONAR Score	12.0*	8.0*	1.1 [1.04, 1.08]*
Mean PD-SONAR Score	2.0*	1.0*	1.0 [1.06, 1.12]*
Mean Physician Global Assessment	4.0*	2.0*	1.4 [1.3, 1.5]*
Mean HAQ Score	0.8*	0.5*	1.6 [1.1, 2.2]*
On biologic, n (%)	61 (33)*	399 (53)*	0.4 [0.3, 0.6]*
On synthetic DMARD, n (%)	110 (60)	500 (66)	0.8 [0.6, 1.1]*

*p<0.05.

Conclusions: In the SCQM RA cohort TS is associated with male gender and an overall higher disease activity. One should actively look for TS even in RA patients in DAS28 remission.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4006

SAT0126 MENTAL HEALTH BENEFITS ASSOCIATED WITH REDUCTION IN DISEASE ACTIVITY AMONG RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW OF THE LITERATURE

V. Strand¹, R. Rendas-Baum², M. Kosinski², D. Brooks³, R. Ganguly³.

¹Stanford University, Palo Alto, CA; ²Optum, Inc., Eden Prairie, MN;

³GlaxoSmithKline, Collegeville, PA, United States

Background: The association between physical functioning and rheumatoid arthritis (RA) disease activity is well established. In randomized controlled trials (RCTs) of RA treatment, reductions in disease activity result in improved physical functioning. The mental health benefits associated with reductions in disease activity are less well recognized.

Objectives: Investigate the association between reductions in RA disease activity and measures of mental health status.

Methods: A systematic review of the published literature of RCTs in RA was conducted. The search was limited to those published in the last 10 years that included the Short-Form (SF)-36 Health Survey as an outcome measure.

Results: The search strategy yielded 77 articles of which 38 were excluded for the following reasons: not RCT (23); focus exclusively on early RA (9); psychometric evaluation (4); review study (1); and off topic (1). Of the 39 articles reporting mean changes in scores on the SF-36 mental health (MH) and role emotional (RE) domains by treatment group, 3 articles also presented these changes in association with reductions in RA disease activity measures.¹⁻³ In relation to American College of Rheumatology (ACR) response criteria, small to moderate (0.2–0.5 standard deviation [SD]) effect size changes in RE and MH domain scores were observed among RA patients whose ACR responses ranged from 20–49%. Moderate to large effect sizes (0.5–0.8 SD) were reported in RE and MH domain change scores among ACR50 responders. Similar changes in RE and MH domain scores were reported by patients with reductions in Simplified Disease Activity Index (SDAI) of ≥ 10 points.

Conclusions: The benefits of clinically meaningful reductions in disease activity among RA patients not only include improved physical functioning but also meaningful improvements in overall mental health status. The improvement in mental health is positively associated with reduction in disease activity, with only small to moderate improvements associated with less than ACR50 responses. Additional work is needed to investigate the incremental effects of RA therapies on mental health beyond the effects related to improvements in disease activity.

References:

[1] Emery P, et al. *J Rheumatol*. 2006;33(4):681–689.

[2] Russell AS, et al. *Ann Rheum Dis*. 2007;66(2):189–194.

[3] Strand V, et al. *Health Qual Life Outcomes*. 2014;12:31.

Disclosure of Interest: V. Strand Consultant for: Abbvie, Amgen, AstraZeneca, BiogenIdec, Boehringer Ingelheim, Celltrion, Crescendo, Genentech/Roche, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sanofi and UCB, R. Rendas-Baum Employee of: Optum, M. Kosinski Employee of: Optum, D. Brooks Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, R. Ganguly Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline

DOI: 10.1136/annrheumdis-2017-eular.3568